Controlling the effectiveness of digoxin  by Krohn, Bernard G
intake or plasma levels of lutein in our study, although this could
be undertaken.
A number of epidemiologic studies have now demonstrated an
association between dietary intake or plasma levels of antioxidant
vitamins and the risk of atherosclerotic vascular disease. However,
large-scale randomized trials to test further for a causal relationship
between antioxidant intake and ischemic heart disease have pro-
vided conflicting results (2). Although there is plausible biological
evidence to suggest antioxidants may prevent the early stages of
atherogenesis, it is unknown as to whether they alter the later
processes that produce clinical events. To determine the role of
antioxidant vitamins in atherosclerosis, it may be more appropriate
to examine the relationship between dietary intake or plasma levels
of these vitamins and measures of early atherosclerosis rather than
clinical cardiovascular events (3).
Although we remain very interested in investigating antioxidant
defenses against lipid peroxidation and novel risk factors for
atherosclerosis, we would support the concept that this essential
ongoing research should not distract us from efforts to implement
more proven preventive strategies (4).
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Controlling the Effectiveness of Digoxin
In a recent issue of the Journal, Adams, et al. (1) correctly stated
that: “Patients taking digoxin did significantly better than those
not taking the drug, but the serum concentration did not correlate
with outcome.” Nevertheless, they concluded: “These results sup-
port the possibility that a lower therapeutic goal for serum digoxin
concentration is warranted in patients with heart failure.”
This conclusion is flawed because in individual patients the
concentration of digoxin in the serum does not accurately represent
the amount of digoxin in the tissues where it works. The digoxin
in the serum is only a tiny fraction of the total amount of digoxin
in the body. The total amount of digoxin in the body is easy to
calculate from the doses administered, and it does correlate with
outcome (2–4). Guiding dosage this way allowed high doses of
digoxin (15 to 19 g/kg of lean body weight) to be given to
patients after cardiac operations, and the patients recovered rapidly
(5,6).
Because serum digoxin concentrations poorly guide dosage and
results, contradictions between serum levels and results have been
seen by many doctors. Low serum concentrations of digoxin
appeared in patients who received therapeutic benefits. In contrast,
high serum concentrations of 2.5 ng/ml have been seen in patients
who had no signs or symptoms of toxicity.
Dr. Jelliffe published a method for calculating the milligrams of
digoxin needed to produce a specific peak total body load of
digoxin and to engender a desired therapeutic result (2–4). A safe,
effective amount of peak total body digoxin to treat heart failure is
8 to 10 g/kg of lean body weight. This program is used at the
University of Southern California/Los Angeles County Medical
Center and at several other hospitals.
Studying the effects of digoxin requires knowing the total
amount of digoxin in the body, which controls the amount of
digoxin in the tissues where digoxin works.
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REPLY
We appreciate Dr. Krohn’s interest and comments concerning our
analysis. We believe our conclusions as stated in the study are
correct. While it is true that the serum digoxin concentration
(SDC) is significantly higher than the tissue concentration during
the distributive phase of digoxin dosing (6 to 12 h), both the SDC
and the amount of drug in the body decline in parallel and are
directly related 12 to 24 h post-dose (1). This is the rationale for
the recommendation to always draw the SDC as a trough
concentration—that is, 24 h after the dose (2). This was mandated
in both the PROVED and RADIANCE protocols.
We agree with Dr. Krohn’s statement that total body stores of
digoxin are easy to calculate. Unfortunately, we are unable to do
this for each individual patient in these studies. However, the
dosing guidelines cited by Dr. Krohn are incorporated into the
dosing table that is currently included in the Lanoxin package
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